Ramesh Arjunji, Phd Email & Phone Number

Philadelphia, Pa, Us

Parsippany, New Jersey, United States

Evidence Synthesis (ES) helps to support the value proposition and lifecycle management for an asset by proactively conceptualizing, designing, collecting, and synthesizing “patient-centric” data and convert it to useable, actionable, and pertinent knowledge for patients, physicians, regulators, payers, HTAs, investors, and policy makers. An actionable ES strategy involves the early development of an ES roadmap to incorporate diverse datasets including, but not limited to, pre-clinical, clinical trials, long-term follow-up, registries, natural history, observational datasets (retrospective and prospective), treatment patterns, healthcare resource utilization, primary research to estimate health utilities, and systematic literature reviews across target countries to quantify the incremental benefit (cost-offsets, quality of life gains from reduction in mortality and morbidity) and incremental budget impact for the identified patient population(s) utilizing the comparator(s) therapy.

Cambridge, Massachusetts, United States

For lysosomal storage disorders (LSDs) pipeline (Fabry, Gaucher Type I & III, Cystinosis, Pompe, Hunter Syndrome), I translated the unmet medical needs, disease biology, preclinical knowledge, lentiviral gene therapy MOA, stem cell biology, KOL inputs, existing real-world evidence (RWE), available regulatory guidelines and pathways, and patient/caregiver/payer/HTA preferences to pragmatic evidence generation strategies for future commercial success.Across pipeline assets, I championed the use of disease severity scoring systems, patient and caregiver reported outcomes, activities of daily living, use of multi domain responder index to capture the multi-organ, systemic manifestation of LSDs, capture of healthcare resource utilization (HCRU) as part of clinical trial evidence, and utilization of duration of effect and quality of life measures in the long-term follow up to address payer/patient/physician needs.

Bannockburn, Il

I managed a cross-functional team that delivered the support and rationale for $2.125M price for one-time treatment with Zolgensma for Spinal Muscular Atrophy (SMA) by engagement with ICER (Institute for Clinical and Economic Review). Worked with AveXis and Novartis corporate communications to convey the use of higher cost-effectiveness thresholds for ultra-rare disorders and to address global media enquiries resulting from ICER SMA review and Novartis R&D presentation (November 5, 2018) highlighting the $4M to $5M potential cost-effective price for Zolgensma.I leveraged the positive ICER SMA review and the published AveXis cost-effectiveness and budget impact model for US payer negotiations on Zolgensma access and reimbursement, and for HTA/Payer discussions ex-US including NICE UK, EU, Japan, South Korea, Taiwan, Hong Kong, Australia, Canada, Brazil, and Argentina in preparation for launch in those countries.As part of AveXis and Novartis public responses to ongoing ICER value framework updates, I was instrumental in advocating for differential discounting of health benefits and costs for ultra-rare diseases, shaping Novartis response for proposed cost-offset options to address cost-ineffective comparators, and for expanding the scope of Report -At- A-Glance (RAAG) to provide actionable information to decision makers. I partnered with business development and corporate strategy to provide pricing, access, and reimbursement inputs for due diligence activities for early gene therapy assets.

Upper Providence, Pennsylvania, United States

I advocated for early diagnosis and apheresis (before 1st line treatment) for NY-ESO eligible NSCLC patients (~2% of NSCLC population) for 3rd line treatment with the cell and gene therapy to increase success rate of drug administration and to prepare the patients, physicians, and payers from a reimbursement viewpoint and community-based follow-up care after drug administration. I was successful in incorporating patient reported outcomes (PRO) as part of the cell and gene therapy long-term follow-up (regulatory requirement of 15-year follow-up of more than 1000 patients with large proportion from commercial use). From an access and reimbursement viewpoint, the inclusion of PROs will enable the firm to offer outcomes-based contracts for a faster uptake of the novel treatment by sharing the outcomes risk between payers and the manufacturer.As part of business development, I provided detailed pricing analyses for four due diligence oncology assets, considering the complementary nature of the assets with epigenetics, immune-oncology, and cell and gene inhouse GSK assets.I developed an agency-based, individual level disease model for anthrax and plague spread using the object-oriented programming capability of Excel Visual Basic to demonstrate the value proposition of raxibacumab as an intervention to address the spread of infectious pathogens.

Fort Worth, Texas, United States

To address the declining revenue growth rate for Alcon (Revenue ~$10B, annual growth rate less than 10%), I developed a novel method, using the detailed, monthly financial data on 78 business units (business units from pharmaceutical, surgical, and vision care franchises, subgroups within franchises, and six areas, globally) to rank-order the business units for their contributions to overall revenue growth (the purpose was to identify the five business units when excluded will lead to the maximum possible revenue growth rate for Alcon). This diagnostic tool was adopted by senior management and steps were taken to address the causes for revenue decline for the identified business units.

Lawrenceville, New Jersey, United States

Partnered with Global Commercialization, Market Access & Pricing, Health Outcomes, and country-level affiliates for oncology and immunology pipeline assets to conduct primary and secondary payer research and deliver insights that drove decision making.

Weston, Massachusetts, United States

I developed an innovative budget impact model (received an Innovation Award for my efforts from the Chief Commercial Officer) that enabled the national and regional account directors to retain Avonex as the interferon therapy of choice in the formulary for MS patients in the US. The model, which is disease agnostic, was adopted by a large PBM for its formulary decision making for other disease areas.

Collegeville, Pennsylvania, United States

I analyzed NHANES data using SAS software (developed my own code for data analyses) to support business development and early clinical development to treat obesity-diabetes. My analysis showed that the potential market to treat obesity-diabetes could be more than doubled if the BMI threshold were lowered from the original benchmark of greater than 30 to include values greater than 27.5. The analysis was well received within Pfizer and few months after my work it was independently replicated by a group of academic researchers and published lending credibility and external validation to my work.

Hawthorne, New York, United States

I developed a pricing model for neratinib plus capecitabine versus trastuzumab for HER2+ breast cancer that was well received by the manufacturer, Wyeth. The pricing model showed that the price of neratinib could be increased when capecitabine became a generic, a counter-intuitive result (neratinib was subsidizing the price of branded capecitabine and the subsidy decreased when capecitabine became a generic).

Chadds Ford, Pennsylvania, United States

I demonstrated the value of “mirrored sales territories” using past, historical call plan data where hospital sales representatives and specialty sales representatives engaged in dual coverage. The analysis led to Endo contracting with an external agency to expand salesforce size from 700+ to 950+.As part of business development, I performed a preliminary assessment for geographic expansion into Mexico and recommended against it based on the regulatory and commercial risks involved for the lead product Lidoderm.

Horsham, Pennsylvania, United States

I developed a value-based pricing approach (well before VBP was defined) within a month for an in-licensed indication, AA Amyloidosis, a rare condition, using glomerular filtration rate from clinical trial data and quality of life associated with loss of kidney function from secondary data sources. The value-based price recommended by the team was accepted at first pass by the J&J pricing committee chaired by Christine Poon and I was nominated for a Standard-of-Leadership award for my efforts.

Doctor Of Philosophy - Phd, Management Science

Master Of Science - Ms, Mechanical Engineering

Bachelor Of Technology - Btech, Aeronautics/Aviation/Aerospace Science And Technology, General